HomeCompareTSBX vs O

TSBX vs O: Dividend Comparison 2026

TSBX yields 563.38% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TSBX wins by $156404.02M in total portfolio value
10 years
TSBX
TSBX
● Live price
563.38%
Share price
$0.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$156404.05M
Annual income
$115,926,179,183.70
Full TSBX calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — TSBX vs O

📍 TSBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSBXO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSBX + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSBX pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSBX
Annual income on $10K today (after 15% tax)
$47,887.32/yr
After 10yr DRIP, annual income (after tax)
$98,537,252,306.14/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, TSBX beats the other by $98,537,247,968.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSBX + O for your $10,000?

TSBX: 50%O: 50%
100% O50/50100% TSBX
Portfolio after 10yr
$78202.04M
Annual income
$57,963,092,143.22/yr
Blended yield
74.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

TSBX
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Price Target
$0.50
+40.8% upside vs current
Range: $0.50 — $0.50
Altman Z
-23.2
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSBX buys
0
O buys
0
No recent congressional trades found for TSBX or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSBXO
Forward yield563.38%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$156404.05M$34.2K
Annual income after 10y$115,926,179,183.70$5,102.74
Total dividends collected$152979.84M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$0.50$64.00

Year-by-year: TSBX vs O ($10,000, DRIP)

YearTSBX PortfolioTSBX Income/yrO PortfolioO Income/yrGap
1← crossover$67,038$56,338.03$10,818$608.16+$56.2KTSBX
2$424,702$352,971.06$11,787$741.68+$412.9KTSBX
3$2,544,295$2,089,864.53$12,946$911.00+$2.53MTSBX
4$14,423,258$11,700,861.61$14,345$1,127.94+$14.41MTSBX
5$77,424,065$61,991,178.81$16,056$1,409.05+$77.41MTSBX
6$393,842,555$310,998,805.50$18,171$1,777.83+$393.82MTSBX
7$1,899,912,512$1,478,500,978.24$20,820$2,268.21+$1899.89MTSBX
8$8,698,653,014$6,665,746,626.53$24,188$2,929.90+$8698.63MTSBX
9$37,829,785,494$28,522,226,769.44$28,533$3,837.11+$37829.76MTSBX
10$156,404,049,663$115,926,179,183.70$34,235$5,102.74+$156404.02MTSBX

TSBX vs O: Complete Analysis 2026

TSBXStock

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Full TSBX Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this TSBX vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSBX vs SCHDTSBX vs JEPITSBX vs KOTSBX vs MAINTSBX vs STAGTSBX vs ADCTSBX vs NNNTSBX vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.